New Hunan Client, August 26 (Correspondent Zeng Tao) On the afternoon of August 26, the launching ceremony of the phase III clinical research project of recombinant norovirus bivalent vaccine in Hunan Province was held at the CDC of Xiangxi Tujia and Miao Autonomous Prefecture.
Norovirus is a globally important foodborne virus that can cause acute gastroenteritis after infection, typically characterized by vomiting and diarrhoea. Norovirus epidemic infection involves people of all ages and can cause outbreaks, which has become a non-negligible problem affecting the daily health of human beings. To date, no vaccine has been approved to protect against norovirus in the world. The recombinant norovirus bivalent (GI.1/GII.4) vaccine developed by China Institute of Biologics Lanzhou is the world's first norovirus vaccine to enter phase III clinical trials, and Xiangxi is one of the clinical research sites of this project.
The relevant person in charge of Xiangxi CDC said that participating in the phase III clinical research of recombinant norovirus bivalent vaccine is of great significance, which is a useful exploration and practice in Xiangxi in vaccine scientific research and achievement transformation, which is conducive to improving the professional skills of disease prevention staff in Xiangxi, building a multi-level and multidisciplinary personnel echelon, and improving the scientific research ability of disease prevention and control institutions; It is conducive to promoting the development of medical and prevention integration, strengthening the capacity of public health services and disease prevention services; It is conducive to promoting the construction of a healthy Xiangxi, protecting public health and maintaining public health safety.
Gao Lidong, Director of Hunan CDC, Peng Yun, Director of the Prefecture Health Commission, Chen Zhiwei, Director of the Prefecture CDC, Zou Yong, General Manager of Lanzhou Institute of Biological Products Co., Ltd., the sponsor, Wei Pengchong, General Manager of Beijing Simuric Pharmaceutical Technology Co., Ltd., and other enterprise leaders attended the launching ceremony. Huang Tao and Dai Defang, experts from the Provincial Center for Disease Control and Prevention, gave on-site lectures and participated in pre-research intensive training and group exercises.